CALMA enrolled people with agitation in Alzheimer’s dementia at sites across the U.S. and Canada. Participants receive investigational IGC-AD1 or placebo for six weeks. $IGC
igcpharma.com/igc-ad1-phase-…
1
102
Our 2026 Annual Meeting of Shareholders is Wednesday, Dec 2, at 11:00 a.m. ET in Potomac, Maryland.
Our annual letter to shareholders is out now. $IGC
investor.igcpharma.com/proxy…
1
84
Agitation in Alzheimer’s can look like restlessness, yelling or pushing back against help with everyday tasks.
It’s one of the hardest parts of the disease for families to manage. $IGC
Thank you to the investigators and site teams running CALMA, our Phase 2 trial of investigational IGC-AD1, across the U.S. and Canada. $IGC
Our scientists published a new review in Academia Drug Development and Pharmacotherapy on how the endocannabinoid system regulates inflammation in the Alzheimer’s brain, drawing on research from 2002 to 2026. $IGC
academia.edu/3071-2521/2/4/1…
2
110
Evelyn Gutiérrez, our Associate Director of Research and Clinical Trials, on what drives her work in Alzheimer’s research. $IGC
1
90
November is National Alzheimer’s Disease Awareness Month and National Family Caregivers Month.
Some of the hardest moments in Alzheimer’s come from symptoms beyond memory loss, like agitation.
Agitation is the focus of CALMA, our Phase 2 trial of investigational IGC-AD1. $IGC
igcpharma.com/igc-ad1-phase-…
2
121
Two ways we’re applying AI to Alzheimer’s:
• MINT-AD, our patent-pending platform for Alzheimer’s risk insights, moving toward real-world use through PRISM
• aha™, which harmonizes research data from different studies
igcpharma.com
2
129
In a double-blind trial, neither participants nor their doctors know who is receiving the investigational drug and who is receiving placebo. It keeps expectations from shaping the results, which is why it’s the standard design for testing a new treatment.
Clinical agitation in Alzheimer’s isn’t a bad mood. It’s a symptom of the disease, and one of the hardest for families to manage.
What it is, in 90 seconds:
#AlzheimersResearch
1
167
Combining Alzheimer’s data from different studies takes researchers hours of manual work.
aha™, our AI tool, cut one representative workflow from 28 hours to 2.5, with a person reviewing the results. It will be deployed on the Alzheimer’s Disease Data Initiative’s (@AlzData) research platform.
Behavioral and psychological symptoms add another layer of complexity to Alzheimer's disease. Their variability is one reason researchers continue to study how they develop and change over time.
#AlzheimersResearch
PRISM is the latest step in IGC Pharma's Alzheimer's AI strategy
Designed to bring the patent-pending MINT-AD platform closer to real-world healthcare applications, PRISM is intended to move AI-generated Alzheimer's risk insights into action
Read more: igcpharma.com/igc-pharma-unv…
#AlzheimersResearch
Most people associate Alzheimer's disease with memory loss
But researchers believe biological changes associated with Alzheimer's may begin 10–20 years before symptoms become noticeable
Alzheimer's Association (2026)
#AlzheimersResearch
↓
Studying Alzheimer's before symptoms appear helps researchers investigate the disease at its earliest stages, before significant damage has occurred
This may help improve how clinical studies are designed and how potential therapies are evaluated
National Institute on Aging (2025)
1
26
Understanding what happens before symptoms appear is one of the keys to advancing Alzheimer's research
#Neuroscience #BrainHealth
24










